Sanofi-Aventis S.A. (SNY)
$43.41 0.00 (0.00%)
17:16 EST SNY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 107.59B
PE Ratio 29.04
Volume (Avg. Vol.)
Day's Range 43.41 - 43.41
52-Week Range -
Dividend & Yield 1.86 (4.29%)
SNY Stock Predictions, Articles, and Sanofi-Aventis S.A. News
- From InvestorPlace
- From the Web
Sanofi SA (NYSE:SNY) is classified as a member of the 135 company Pharmaceuticals GICS industry group, which is a segment of the 783 company GICS Health Care sector. SNY's market value is $124.3 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 2 among the 135 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 18 among the 783 companies in the sector, and number 194 in the nearly 5,000 company Portfolio Grader universe.
Currently, Sanofi SA (NYSE:SNY) has a Strong Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. This represents no change from the previous week and is the same ranking SNY has had from Portfolio Grader for the last month.
Alnylam Pharmaceuticals (ALNY) shares skyrocketed more than 50% on Wednesday morning on the news that the company's latest drug impressed.
French stocks like AFLYY, SNY and ORAN are making headlines as the nation's tightly contested presidential race approaches the finish line.
Shares of Johnson & Johnson slid in trading Tuesday after first-quarter earnings results disappointed. Here's where to turn in pharma today
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
3 Stocks to Watch on Monday: Tesla Inc (TSLA), Sanofi SA (ADR) (SNY) and Imagination Technologies Group plc (IMG)
Tesla (TSLA) beats estimates for Q1 deliveries, a Sanofi (SNY) drug delivers and Imagination Technologies (IMG) craters more than 60%.
Flexion (FLXN) may soon be acquiring Sanofi (SNY) to boost its arthritis medications portfolio. Here's what you should know about the deal.
Fans of dividends don't have to completely abandon all hope for growth too -- these top pharmaceutical stocks offer the best of both worlds.
Amgen (AMGN) reports Q4 earnings on Thursday, and if something does weigh on AMGN stock, it'll likely be one of these three factors.
Uncertainty, optimism and good liquidity are good reasons to consider an Amgen spread in lieu of AMGN stock in front of earnings.
Things are finally turning around for income investors, and we've found these stocks to help maximize your gains
3 Stocks to Watch on Wednesday: Tesla Motors Inc (TSLA), Agile Therapeutics Inc (AGRX) and Regeneron Pharmaceuticals Inc (REGN)
Tesla Motors (TSLA) dips on a vehicle deliveries miss, Agile Therapeutics (AGRX) tanks on trial results and Regeneron (REGN) suffers a legal defeat.
By Richard Band
Sanofi has a rough time during 2016, but after the U.S. presidential election and with several forward-looking decisions, SNY stock is a buy.
Regeneron Pharmaceuticals Inc (REGN) stock was up on Friday following mixed results in its earnings report for the third quarter of 2016.
Pfizer missed on earnings, and PFE stock slipped as a result. But even if you don't own Pfizer, you don't want to ignore what's happening there.
Sanofi (SNY) is suing Merck (MRK) for what it claims are several instances of patent infringement connected to its diabetes drug Lantus.
Navellier RatingsPowered by Portfolio Grader